Results 191 to 200 of about 56,276 (247)

Development and validation of an antidrug antibody assay for TRK-950 using Melon™ gel and SPEAD pretreatment. [PDF]

Bioanalysis
Nishio R, Nakanaga K, Yoshinaga R, Kurihara A, Okano F.   +4 more
europepmc   +1 more source

Efficacy and safety of CT‐P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16‐week follow‐up study

Clinical and Translational Allergy, Volume 15, Issue 6, June 2025.
Abstract Background A double‐blind, randomized Phase 3 study (NCT04426890) confirmed that CT‐P39 and European Union‐approved reference omalizumab (ref‐OMA) were comparable in terms of efficacy, quality of life (QoL), pharmacokinetics (PK), pharmacodynamics (PD), safety, and immunogenicity up to week 24.
Clive Grattan, Yevgeniya Dytyatkovska, Michał Springer, Maria Ratkova, Borislava Krusheva, Izabella Krupa‐Borek, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Yunju Bae, Suyoung Kim, Sewon Lee, Eunjin An, Jeong Eun Park, Jieun Ka, Jongho Kim, Sarbjit S. Saini   +17 more
wiley   +1 more source

Targeting the chemokine receptor CXCR4 for cancer therapies. [PDF]

Biomark Res
Rueda A, Serna N, Mangues R, Villaverde A, Unzueta U.   +4 more
europepmc   +1 more source

LP‐003, a novel high‐affinity anti‐IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double‐blind, placebo‐controlled phase 2 clinical trial

Clinical and Translational Allergy, Volume 15, Issue 6, June 2025.
Abstract Background Anti‐IgE therapy can serve as an option for inadequately controlled seasonal allergic rhinitis (SAR) patients. LP‐003, a novel anti‐IgE antibody, is being tested as an add‐on treatment for SAR. This trial aimed to evaluate whether LP‐003 is effective and safe for SAR.
Kai Guan, Shuang Liu, Yan Feng, Lisha Li, Xiaoming Zhu, Nai‐Chau‐Sun Bill, Haili Ma, Jie Yang, Cuicui Han, Heng Liu, Qingyu Wei, Haiyun Shi, Xueyan Wang   +12 more
wiley   +1 more source

CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity. [PDF]

J Immunother Cancer
Whalen KA, Henry CC, Mehta NK, Rakhra K, Yalcin S, Meetze K, Gibson NW, Baeuerle PA, Michaelson JS.   +8 more
europepmc   +1 more source

An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti‐Angiogenic Agents for Therapy: A Case Report

Cancer Reports, Volume 8, Issue 6, June 2025.
ABSTRACT Background Although the presence of Kirsten murine sarcoma virus (KRAS) mutations predicts a failure of non‐small cell carcinoma (NSCLC) patients to benefit from epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) therapy it may be more sensitive to programmed combination therapy of programmed death 1 (PD‐1)/programmed ...
Li Wang, Jiaqi Wu, Ping Shao, Wuping Bao, Lin Mao, Zhendong Pan, Aihua Bao, Min Zhang, Zhenghua Wu, Guorong Fan   +9 more
wiley   +1 more source

Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates. [PDF]

Cell Death Discov
Yin Q, Zhang Y, Xie X, Hou M, Chen X, Ding J.   +5 more
europepmc   +1 more source

Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders. [PDF]

BioDrugs
Holian AH, Weinshenker BG.
europepmc   +1 more source

Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies. [PDF]

Discov Oncol
Ebinama U, George B.
europepmc   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source